Comparison

KAAD-Cyclopamine European Partner

Item no. TMO-T35558-5mg
Manufacturer TargetMol
CASRN 306387-90-6
Amount 5 mg
Quantity options 1 mg 5 mg
Category
Type Inhibitors
Specific against other
Smiles C[C@H]1[C@]2(C(C)=C3[C@@](CC2)([C@]4([C@](C3)([C@]5(C)C(=CC4)CC(=O)CC5)[H])[H])[H])O[C@]6([C@]1(N(CCNC(CCCCCNC(CCC7=CC=CC=C7)=O)=O)C[C@@H](C)C6)[H])[H]
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Shipping Condition Cool pack
Available
Manufacturer - Targets
Others
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
697.99
Description
Cyclopamine-KAAD is a potent inhibitor of hedgehog signaling with an IC50 value of 20 nM in a Shh-LIGHT2 assay. It blocks binding of BODIPY-cyclopamine to cells expressing Smoothened (Smo) in a dose-dependent manner. Cyclopamine-KAAD is cell-permeable and binds to SmoA1 to promote its exit from the endoplasmic reticulum. It inhibits the invasion and migration (45.9 and 43.3% inhibition, respectively) of Bel-7402 hepatocarcinoma cells and decreases the expression of nuclear glioma-associated oncogene 1 (Gli1) and cytosolic MMP-9, pERK1, and pERK2 proteins in a dose-dependent manner. Cyclopamine-KAAD also increases TRAIL-mediated cell death in NCH82 and NCH89 human glioblastoma cultures and upregulates expression of the death receptors DR4 and DR5 in LN229 and U251 glioma cells.
Pathways
Others

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close